http://orcid.org/0000-0003-2795-6507
References
- Brown JR, Hillmen P, O’Brien S, et al. Extended followup and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83–91.
- Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997–1007.
- Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–1120.
- Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437.
- Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
- De Vecchis R, Ariano C, Rigopoulos A, et al. Illustrating the sense of a Network Meta-Analysis by means of dedicated plots: A way for making it conceptually easier and more immediately understandable. J Clin Med Res. 2018;10(9):732–735.
- Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4(3):e114–e126.
- Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311.
- Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–211.
- Huang X, Qiu L, Jin J, et al. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study. Cancer Med. 2018;7(4):1043–1055.
- Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–2455.
- Mato A, Follows G, Sail K, et al. Indirect treatment comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed refractory chronic lymphocytic leukemia. 23rd Congress of the European Hematology Association, Jun 14–17, 2018. Stockholm, abstr PF 358.
- Hillmen P, Fraser G, Jones J, et al. Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in patients with previously treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): an indirect comparison of the RESONATE and HELIOS Trials. Blood. 2015;126(23):2944.
- Chen PH, Ho CL, Lin C, et al. Treatment outcomes of novel targeted agents in relapse/refractory chronic lymphocytic leukemia: a systematic review and network Meta-Analysis. J Clin Med. 2019;8(5):737.